Pneumococcal Vaccine Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Pneumococcal Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Conjugate Vaccines, Polysaccharide Vaccines), By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis), By Product (Pneumovax23, Prevnar 13, Synflorix), By Distribution (Government Authorities, Non-Governmental Organizations), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The global pneumococcal vaccine market is projected to expand significantly, from USD 9.71 billion in 2025 to USD 13.98 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 6.26%. This market primarily consists of conjugate and polysaccharide vaccines developed to combat Streptococcus pneumoniae. Growth is largely propelled by an increase in pneumococcal diseases, the expansion of national immunization initiatives, and a growing elderly population prone to respiratory infections, driving demand for preventative solutions across all economies.
However, high manufacturing and procurement costs pose a substantial challenge, restricting access in developing regions and impeding the complete rollout of immunization programs. Data from the World Health Organization in 2024 indicates that while 163 Member States had introduced the vaccine, achieving 67% global third-dose coverage, these disparities underscore ongoing difficulties in ensuring fair supply and funding for sustained market expansion.
Market Driver
Two primary factors are fueling the global pneumococcal vaccine market. First, the expansion of government-led national immunization programs, especially in low- and middle-income countries where access has been limited, is a major driver. International partnerships with local governments are increasingly sharing the financial load of vaccine implementation, fostering sustainable procurement. This cost-sharing model not only ensures consistent demand for manufacturers but also promotes the inclusion of pneumococcal conjugate vaccines in routine schedules. Gavi, the Vaccine Alliance, reported in its 2024 Annual Progress Report that country co-financing for Gavi-supported vaccines hit a record US$255 million in 2024, indicating a significant rise in domestic financial commitment to immunization.
Second, the increasing geriatric population, highly susceptible to pneumococcal infections, is boosting demand for advanced prophylactic vaccines globally. As immunity weakens with age, the elderly are at a higher risk of severe invasive pneumococcal disease, necessitating focused adult vaccination efforts. Data from the Institute of Environmental Science and Research's 2024 report showed that adults aged 65 and above had the highest incidence of IPD at 34.2 per 100,000. Pharmaceutical giants like Pfizer capitalize on this demand; their Third-Quarter 2025 Results reported total revenues of $16.7 billion, partly driven by the strong performance of their Prevnar vaccine family.
Market Challenge
The most significant obstacle to the pneumococcal vaccine market's growth, particularly in lower and middle-income countries, is the elevated cost of vaccine manufacturing and procurement. The intricate biological processes involved in producing conjugate vaccines demand substantial capital, leading to high prices that burden national health budgets. This financial pressure often forces developing nations to depend on external aid for immunization programs, as they struggle to self-finance procurement. When governments face budget limitations, it results in delayed purchases or restricted rollout, directly hindering vaccine uptake and market volume growth in these crucial regions.
This financial strain is quantifiable through the increasing monetary obligations placed on developing economies. Gavi, the Vaccine Alliance, reported that in 2024, lower-income countries contributed nearly US$255 million to their own vaccination programs through co-financing, a 19% increase from the prior year. This rising financial strain highlights the ongoing difficulty for resource-limited nations to maintain widespread immunization coverage, thereby constraining the market's full expansion without continuous external financial support.
Market Trends
The pneumococcal vaccine market is undergoing significant transformation, marked by two key trends. Firstly, there's an accelerated move towards ultra-high valency conjugate vaccines, with manufacturers striving to offer broader serotype coverage beyond current 20-valent options. This shift aims to counter the "replacement phenomenon," where non-vaccine serotypes cause disease, leading to rapid development and commercialization of next-generation PCVs, particularly for adults. The market has shown strong acceptance of these broader-spectrum vaccines, as exemplified by Merck & Co., Inc.'s newly launched 21-valent vaccine, Capvaxive, which generated US$244 million in sales in Q3 2025 due to robust demand. This highlights the clinical importance of expanded valency in reducing invasive pneumococcal disease.
Secondly, the rise of cost-effective indigenous vaccine manufacturing in developing regions is disrupting the traditional dominance of Western multinational companies. Local biotechnology firms, especially in India, are rapidly increasing production to meet demand in the Global South, thus reducing dependency on external aid and mitigating international procurement delays. This strategic expansion is backed by significant investments in infrastructure and research to ensure independent supply security. For instance, Biological E. Limited committed ₹4,000 crore to establish advanced vaccine facilities, demonstrating the crucial role of such investments in providing affordable pneumococcal vaccines globally and ensuring fair access in low- and middle-income countries.
Key Market Players
* GSK PLC
* Pfizer Inc
* Merck KGaA
* Serum Institute of India Pvt Ltd
* CSL Ltd
* Sanofi SA
* Walvax Biotechnology Co., Ltd
* Beijing Minhai Biotechnology Limited Company
* AstraZeneca PLC
* BioNTech
Report Scope
In this report, the Global Pneumococcal Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Pneumococcal Vaccine Market, By Type
* Conjugate Vaccines
* Polysaccharide Vaccines
# Pneumococcal Vaccine Market, By Indication
* Bronchitis
* Meningitis
* Pneumonia
* Sepsis
# Pneumococcal Vaccine Market, By Product
* Pneumovax23
* Prevnar 13
* Synflorix
# Pneumococcal Vaccine Market, By Distribution
* Government Authorities
* Non-Governmental Organizations
# Pneumococcal Vaccine Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Pneumococcal Vaccine Market.
Available Customizations:
Global Pneumococcal Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Pneumococcal Vaccine Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
5.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
5.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
5.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Pneumococcal Vaccine Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Indication
6.2.3. By Product
6.2.4. By Distribution
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Pneumococcal Vaccine Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Indication
6.3.1.2.3. By Product
6.3.1.2.4. By Distribution
6.3.2. Canada Pneumococcal Vaccine Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Indication
6.3.2.2.3. By Product
6.3.2.2.4. By Distribution
6.3.3. Mexico Pneumococcal Vaccine Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Indication
6.3.3.2.3. By Product
6.3.3.2.4. By Distribution
7. Europe Pneumococcal Vaccine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Indication
7.2.3. By Product
7.2.4. By Distribution
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Pneumococcal Vaccine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Indication
7.3.1.2.3. By Product
7.3.1.2.4. By Distribution
7.3.2. France Pneumococcal Vaccine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Indication
7.3.2.2.3. By Product
7.3.2.2.4. By Distribution
7.3.3. United Kingdom Pneumococcal Vaccine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Indication
7.3.3.2.3. By Product
7.3.3.2.4. By Distribution
7.3.4. Italy Pneumococcal Vaccine Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Indication
7.3.4.2.3. By Product
7.3.4.2.4. By Distribution
7.3.5. Spain Pneumococcal Vaccine Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Indication
7.3.5.2.3. By Product
7.3.5.2.4. By Distribution
8. Asia Pacific Pneumococcal Vaccine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Indication
8.2.3. By Product
8.2.4. By Distribution
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Pneumococcal Vaccine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Indication
8.3.1.2.3. By Product
8.3.1.2.4. By Distribution
8.3.2. India Pneumococcal Vaccine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Indication
8.3.2.2.3. By Product
8.3.2.2.4. By Distribution
8.3.3. Japan Pneumococcal Vaccine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Indication
8.3.3.2.3. By Product
8.3.3.2.4. By Distribution
8.3.4. South Korea Pneumococcal Vaccine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Indication
8.3.4.2.3. By Product
8.3.4.2.4. By Distribution
8.3.5. Australia Pneumococcal Vaccine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Indication
8.3.5.2.3. By Product
8.3.5.2.4. By Distribution
9. Middle East & Africa Pneumococcal Vaccine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Indication
9.2.3. By Product
9.2.4. By Distribution
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Pneumococcal Vaccine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Indication
9.3.1.2.3. By Product
9.3.1.2.4. By Distribution
9.3.2. UAE Pneumococcal Vaccine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Indication
9.3.2.2.3. By Product
9.3.2.2.4. By Distribution
9.3.3. South Africa Pneumococcal Vaccine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Indication
9.3.3.2.3. By Product
9.3.3.2.4. By Distribution
10. South America Pneumococcal Vaccine Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Indication
10.2.3. By Product
10.2.4. By Distribution
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Pneumococcal Vaccine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Indication
10.3.1.2.3. By Product
10.3.1.2.4. By Distribution
10.3.2. Colombia Pneumococcal Vaccine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Indication
10.3.2.2.3. By Product
10.3.2.2.4. By Distribution
10.3.3. Argentina Pneumococcal Vaccine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Indication
10.3.3.2.3. By Product
10.3.3.2.4. By Distribution
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Pneumococcal Vaccine Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. GSK PLC
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Pfizer Inc
15.3. Merck KGaA
15.4. Serum Institute of India Pvt Ltd
15.5. CSL Ltd
15.6. Sanofi SA
15.7. Walvax Biotechnology Co., Ltd
15.8. Beijing Minhai Biotechnology Limited Company
15.9. AstraZeneca PLC
15.10. BioNTech
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們